BLRX logo

BioLineRx Ltd.

BLRX
Healthcare|Biotechnology|IL
$1.71
-0.06 (-3.28%)
DCF Value
$0.18
Tangible Book / Share
$0.00
Cash / Share
$0.07
Next Earnings Report
Nov 23, 2026
EPS est. -$0.39 · Revenue est. $357.5K
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Oct 2, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Dec 2020
P3
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
NCT03246529

Recent Press Releases

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
Oct 23, 2026 · PRNewsWire
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
Oct 8, 2026 · PRNewsWire
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Sep 10, 2026 · PRNewsWire
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 31, 2026 · PRNewsWire
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
Aug 28, 2026 · PRNewsWire
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
Aug 25, 2026 · PRNewsWire

SEC Filings (46)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 23, 20266-KForeign issuer reportDocumentIndex
Oct 2, 2026EFFECTDocumentIndex
Oct 2, 2026424B3Offering prospectusDocumentIndex
Sep 25, 2026F-1IPO / offering registrationDocumentIndex
Sep 24, 20266-KForeign issuer reportDocumentIndex
Sep 10, 20266-KForeign issuer reportDocumentIndex
Sep 9, 2026DDocumentIndex
Aug 31, 2026424B5Offering prospectusDocumentIndex
Aug 31, 20266-KForeign issuer reportDocumentIndex
Aug 31, 20266-KForeign issuer reportDocumentIndex
Aug 28, 20266-KForeign issuer reportDocumentIndex
Aug 18, 20266-KForeign issuer reportDocumentIndex
Jul 8, 20266-KForeign issuer reportDocumentIndex
May 27, 20266-KForeign issuer reportDocumentIndex
May 22, 20266-KForeign issuer reportDocumentIndex
May 19, 20266-KForeign issuer reportDocumentIndex
Apr 28, 20266-KForeign issuer reportDocumentIndex
Mar 27, 202620-F/AAnnual report (foreign)DocumentIndex
Mar 26, 20266-KForeign issuer reportDocumentIndex
Mar 23, 20266-KForeign issuer reportDocumentIndex
Mar 23, 202620-FAnnual report (foreign)DocumentIndex
Feb 23, 20266-KForeign issuer reportDocumentIndex
Jan 23, 2026S-8Employee stock planDocumentIndex
Nov 24, 20256-KForeign issuer reportDocumentIndex
Nov 17, 20256-KForeign issuer reportDocumentIndex
Sep 29, 20256-KForeign issuer reportDocumentIndex
Aug 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 20256-KForeign issuer reportDocumentIndex
Jul 25, 2025424B5Offering prospectusDocumentIndex
Jun 30, 20256-KForeign issuer reportDocumentIndex
May 30, 20256-KForeign issuer reportDocumentIndex
May 27, 20256-KForeign issuer reportDocumentIndex
May 23, 20256-KForeign issuer reportDocumentIndex
Mar 31, 20256-KForeign issuer reportDocumentIndex
Mar 31, 202520-FAnnual report (foreign)DocumentIndex
Jan 21, 20256-KForeign issuer reportDocumentIndex
Jan 17, 20256-KForeign issuer reportDocumentIndex
Jan 10, 2025SC 13GPassive 5%+ stakeDocumentIndex
Jan 7, 20256-KForeign issuer reportDocumentIndex
Jan 7, 2025424B5Offering prospectusDocumentIndex